มะเร็งต่อมน้ำเหลืองในประเทศไทย
-
Keywords:
Lymphoma, ThailandAbstract
-
Downloads
References
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720-48.
Intragumtornchai T, Bunworasate U, Wudhikarn K, et al. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol. 2017;1-9.
Choeyprasert W, Anurathapan U, Pakakasama S, et al. Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. Pediatr Int. 2019;61:49-57.
Nanthakwang N, Rattarittamrong E, Rattanathammethee T, et al. Clinicopathological study and outcomes of with primary extranodal lymphoma. Hematol Rep. 2019;11:89-93.
Owattanapanich W, Ruchutrakoola T, Pongpruttipanb T, Maneerattanaporn M. A 10-year cohort study of 175 primary gastrointestinal lymphoma cases in Thailand: clinical features and outcomes in the immunochemotherapy era. Hematology. 2021;26:249-55.
Vittayawacharin P, Khuhapinant A. A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand. Hematology. 2021;26:75-82.
Pruksaeakanan C, Teyateeti P, Patthamalai P, Thumrongtharadol J, Chairatchaneeboon M. Primary cutaneous lymphomas in Thailand: A 10-year retrospective study. BioMed Res Int. 2021;4057661.
Intragumtornchai T, Bunworasate U, Siritanaratkul N, et al. Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessibility. Leuk Lymphoma. 2013;54:83-9.
Jitraknatee J, Norasetthada L, Tantiworawit A, Rattarittamrong E, Chai-adisaksopha C, Nawarawong W. The efficacy of ESHAP without stem cell transplantation as a salvage therapy for relapsed or refractory non-Hodgkin lymphoma: A single center experience from Maharaj Nakorn Chiang Mai Hospital. J Hematol Transfus Med. 2012;22:247-58.
Boonyarat R, Chansung K, Sirijeerachai C, Lanamtieng T. Retrospective Study of Efficacy and Safety of Various Salvage Chemotherapy Regimens in Relapsed or Refractory Lymphoma. J Hematol Transfus Med. 2021;31:327-35.
Sopittapan T, Tunthanathip T, Kaewborisutsakul A. Outcome and prognostic factors of primary central nervous system lymphoma in southern Thailand. Asian J Neurosurg. 2020;15:560-5.
Chanswangphuwana C, Rojnuckarin P, Cherdchoo N, Raiyawa T, Uaprasert N. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience. Hematology. 2018;23:385-90.
Piriyakhuntorn P, Rattanathammethee T, Hantrakool S, et al. Outcome of patients with newly diagnosed primary CNS lymphoma after highdose methotrexate followed by consolidation wholebrain radiotherapy and cytarabine: an 8 year cohort study. Int J Clin Oncol. 2021;26:1805–11.
Rattarittamrong E, Norasetthada L, Tantiworawit A, Chai-Adisaksopha C, Nawarawong W. CHOEP-21 Chemotherapy for newly diagnosed nodal peripheral T-Cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thai. 2013;96:1416-22.
Norasetthada L, Tantiworawit A, Rattanathammethee T, Chai-Adisaksopha C, Chaipoh T, Rattarittamrong E. Efficacy of ESHAP regimen in transplant ineligible patients with relapsed/refractory T-cell lymphoma. J Hematol. 2018;7:131-9.
Girdwichai N, Nolwachai, N, Promrattanakun A. Cyclosporine and prednisolone as first-line treatment of subcutaneous panniculitis-like T cell lymphoma: Clinical features and outcomes in 4 patients. Greater Mekong Sub-Region Medical Journal. 2021;2:15-23.
Rojnuckarin P, Na Nakorn T, Assanasen T, Wannakrairot P, Intragumtornchai T. Cyclosporin in subcutaneous panniculitislike T-cell lymphoma. Leuk Lymphoma. 2007;48:560-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
